Lucinactant approved to treat breathing distress

Article

The US Food and Drug Administration has approved lucinactant, a new surfactant that prevents respiratory distress syndrome, most common in babies born 6 weeks or more before their due dates.

The US Food and Drug Administration (FDA) has approved lucinactant, a new surfactant that prevents respiratory distress syndrome (RDS), most common in babies born 6 weeks or more before their due dates.

A single multidose study proved lucinactant's safety and efficacy compared with other FDA-approved surfactants. In the study, 1,294 premature infants were given lucinactant, colfosceril palmitate, or beractant within 30 minutes of birth. The infants who received lucinactant demonstrated significant improvement in RDS at 24 hours and in RDS-related mortality through 2 weeks compared with infants who received the other surfactants.

The most common side effects of lucinactant are related to administration through the infant's endotracheal tube and include tube reflux or obstruction, pale skin, and dose interruption.

Related Videos
Carissa Baker-Smith
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
Allison Scott, DNP, CPNP-PC, IBCLC
Joanne M. Howard, MSN, MA, RN, CPNP-PC, PMHS & Anne Craig, MSN, RN, CPNP-PC
Juanita Mora, MD
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
© 2024 MJH Life Sciences

All rights reserved.